Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction

European Journal of Heart Failure

Volumn 10, Issue 4, 2008, Pages 334-342

  Jacobshagen, Claudius ^a   Grüber, Meike ^a   Teucher, Nils ^a   Schmidt, Albrecht G ^a   Unsöld, Bernhard W ^a   Toischer, Karl ^a   Nguyen Van, Phuc ^a   Maier, Lars S ^a   Kögler, Harald ^a   Hasenfuss, Gerd ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Akt signalling; Aortic banding; Celecoxib; Heart failure; Hypertrophy

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CELECOXIB; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXPERIMENTAL RABBIT; FEMALE; GENE EXPRESSION; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD PRESSURE; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HEART FAILURE; INSULIN; MICE; MICE, INBRED C57BL; MUSCLE PROTEINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; PHENYLEPHRINE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRAZOLES; RABBITS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SULFONAMIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 41449117606     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.02.013     Document Type: Article

References (52)

1. Selvetella G., Hirsch E., Notte A., Tarone G., and Lembo G. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 63 (2004) 373-380
2. Heineke J., and Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7 (2006) 589-600
3. Frey N., Katus H.A., Olson E.N., and Hill J.A. Hypertrophy of the heart: a new therapeutic target?. Circulation 109 (2004) 1580-1589
4. Schluter K.D., and Wollert K.C. Synchronization and integration of multiple hypertrophic pathways in the heart. Cardiovasc Res 63 (2004) 367-372
5. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
6. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., and Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114 (1991) 345-352
7. Vakili B.A., Okin P.M., and Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 141 (2001) 334-341
8. Maron B.J., and Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation 114 (2006) 1633-1644
9. Pluim B.M., Zwinderman A.H., van der Laarse A., and van der Wall E.E. The athletes heart: a meta-analysis of cardiac structure and function. Circulation 101 (2000) 336-344
10. Wilkins B.J., Dai Y.S., Bueno O.F., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94 (2004) 110-118
11. DeBosch B., Treskov I., Lupu T.S., et al. Akt1 is required for physiological cardiac growth. Circulation 113 (2006) 2097-2104
12. McMullen J.R., Shioi T., Zhang L., et al. Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100 (2003) 12355-12360
13. Matsui T., Li L., Wu J.C., et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277 (2002) 22896-22901
14. Shiojima I., Sato K., Izumiya Y., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115 (2005) 2108-2118
15. O'Neill B.T., and Abel E.D. Akt1 in the cardiovascular system: friend or foe?. J Clin Invest 115 (2005) 2059-2064
16. Yang H.M., Kim H.S., Park K.W., et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110 (2004) 301-308
17. Wu T., Leng J., Han C., and Demetris A.J. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3 (2004) 299-307
18. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275 (2000) 11397-11403
19. Donahue J.K., Kikkawa K., Johns D.C., Marban E., and Lawrence J.H. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci USA 94 (1997) 4664-4668
20. Cohen P., and Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2 (2001) 769-776
21. Schluter K.D., Goldberg Y., Taimor G., Schafer M., and Piper H.M. Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes. Cardiovasc Res 40 (1998) 174-181
22. Hu P., Zhang D., Swenson L., Chakrabarti G., Abel E.D., and Litwin S.E. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 285 (2003) H1261-H1269
23. Schmidt A.G., Kadambi V.J., Ball N., et al. Cardiac-specific overexpression of calsequestrin results in left ventricular hypertrophy, depressed force-frequency relation and pulsus alternans in vivo. J Mol Cell Cardiol 32 (2000) 1735-1744
24. Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., and Backx P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37 (2004) 449-471
25. Hardt S.E., and Sadoshima J. Glycogen Synthase Kinase-3β: a novel regulator of cardiac hypertrophy and development. Circ Res 90 (2002) 1055-1063
26. Hunter J.J., and Chien K.R. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341 (1999) 1276-1283
27. Nagoshi T., Matsui T., Aoyama T., et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 115 (2005) 2128-2138
28. Shioi T., McMullen J.R., Kang P.M., et al. Akt/Protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22 (2002) 2799-2809
29. McMullen J.R., Shioi T., Huang W.Y., et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110α) pathway. J Biol Chem 279 (2004) 4782-4793
30. Shioi T., Kang P.M., Douglas P.S., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19 (2000) 2537-2548
31. Yamashita K., Kajstura J., Discher D.J., et al. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res 88 (2001) 609-614
32. Esposito G., Rapacciuolo A., Naga Prasad S.V., et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105 (2002) 85-92
33. Hill J.A., Rothermel B., Yoo K.D., et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem 277 (2002) 10251-10255
34. Rothermel B.A., McKinsey T.A., Vega R.B., et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98 (2001) 3328-3333
35. Hill J.A., Karimi M., Kutschke W., et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101 (2000) 2863-2869
36. Sanbe A., Gulick J., Hanks M.C., Liang Q., Osinska H., and Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 92 (2003) 609-616
37. Antos C.L., McKinsey T.A., Frey N., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99 (2002) 907-912
38. Shioi T., McMullen J.R., Tarnavski O., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107 (2003) 1664-1670
39. McMullen J.R., Sherwood M.C., Tarnavski O., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109 (2004) 3050-3055
40. Haq S., Choukroun G., Lim H., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 103 (2001) 670-677
41. Baba H.A., Stypmann J., Grabellus F., et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res 59 (2003) 390-399
42. Andersohn F., Suissa S., and Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 113 (2006) 1950-1957
43. Gislason G.H., Jacobsen S., Rasmussen J.N., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113 (2006) 2906-2913
44. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
45. Solomon S.D., McMurray J.J.V., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
46. Jugdutt B.I. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation 115 (2007) 288-291
47. Antman E.M., Bennett J.S., Daugherty A., Furberg C., Roberts H., and Taubert K.A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007) 1634-1642
48. Solomon S.D., Pfeffer M.A., McMurray J.J.V., et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 (2006) 1028-1035
49. Zhang J., Ding E.L., and Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296 (2006) 1619-1632
50. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
51. Solomon D.H., Schneeweiss S., Glynn R.J., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109 (2004) 2068-2073
52. Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363 (2004) 1751-1756